Journal of Neural Transmission

, Volume 113, Issue 9, pp 1119–1129 | Cite as

Influence of noradrenaline denervation on MPTP-induced deficits in mice

  • T. Archer
  • A. Fredriksson
Article

Summary.

C57/BL6 mice were administered either DSP4 (50 mg/kg, s.c., 30 min after injection of zimeldine, 20 mg/kg, s.c.) or vehicle (saline) at 63 days of age. Three weeks later, one group (n = 10) of DSP4-treated and one group of vehicle-treated mice were administered MPTP (2 × 40 mg/kg, s.c., 24 hours between injections; the High dose groups), one group (n = 10) of DSP4-treated and one group of vehicle-treated mice were administered MPTP (2 × 20 mg/kg, s.c., 24 hours between injections; the Low dose groups), and one group (n = 10) of DSP4-treated and one group of vehicle-treated mice were administered vehicle. Three weeks later, all six groups were tested in motor activity test chambers, followed by injections of L-Dopa (20 mg/kg, s.c.), and then tested over a further 360 min in the activity test chambers. It was found that pretreatment with the selective NA neurotoxin, DSP4, deteriorated markedly the dose-dependent motor activity deficits observed in the vehicle pretreated MPTP treated mice. These ‘ultra-deficits’ in the spontaneous motor behaviour of MPTP-treated mice were observed over all three parameters: locomotion, rearing and total activity, and were restricted to the 1st and 2nd 20-min periods. Administration of L-Dopa (20 mg/kg) following the 60-min testing of spontaneous behaviour restored the motor activity of Vehicle + MPTP treated mice (neither the Vehicle + MPTP-Low nor the Vehicle + MPTP-High groups differed from the Vehicle–Vehicle group, here) but failed to do so in the DSP4 pretreated mice. Here, a dose-dependent deficit of L-Dopa-induced motor activity (over all three parameters) was obtained thereby offering further evidence of an ‘ultra-deficit’ of function due to previous denervation of the NA terminals. The present findings support the notion that severe damage to the locus coeruleus noradrenergic system, through systemic DSP4, disrupts the facilitatory influence on the nigrostriatal DA system, and interferes with the ability of the nigrostriatal pathway to compensate for or recover from marked injury, MPTP treatment.

Keywords: DSP4, MPTP, vehicle, motor deficits, locomotion, rearing, total activity, L-Dopa, restoration, attenuation, DA, NA, C57/BL6 mice, movement disorder, PD. 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andén, N-E, Grabowska, M 1976Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brainEur J Pharmacol39275282PubMedCrossRefGoogle Scholar
  2. Archer, T 1982Serotonin and fear retention in the ratJ Comp Physiol Psychol96491516PubMedCrossRefGoogle Scholar
  3. Archer, T, Fredriksson, A 2000Effects of clonidine and adrenoceptor antagonists on motor activity in DSP4-treated mice. I. Dose, time- and parameter-dependencyNeurotox Res1235247PubMedGoogle Scholar
  4. Archer, T, Fredriksson, A 2001Effects of α-adrenoceptor agonists in chronic morphine administered DSP4-treated rats: evidence for functional cross-sensitizationNeurotox Res3411432PubMedGoogle Scholar
  5. Archer, T, Fredriksson, A 2003An antihypokinesic action of α2-adrenoceptors upon MPTP-induced behaviour deficits in miceJ Neural Transm110183200PubMedCrossRefGoogle Scholar
  6. Archer, T, Ögren, S-O, Johansson, G, Ross, SB 1982DSP4-induced two-way active avoidance impairment: involvement of central and not peripheral noradrenaline depletionPsychopharmacology76303309PubMedCrossRefGoogle Scholar
  7. Archer, T, Mohammed, AK, Ross, SB, Söderberg, U 1983T-maze learning, spontaneous activity and food intake recovery following systemic administration of the noradrenaline neurotoxin, DSP4Pharmacol Biochem Behav19121130PubMedCrossRefGoogle Scholar
  8. Archer, T, Jonsson, G, Ross, SB 1984A parametric study of the effects of the noradrenaline neurotoxin DSP4 on avoidance acquisition and noradrenaline neurons in the CNS of the ratBr J Pharmacol82249257PubMedGoogle Scholar
  9. Archer, T, Jonsson, G, Ross, SB 1985Active and passive avoidance following the administration of systemic DSP4, xylamine, or p-chloroamphetamineBehav Neural Biol43238249PubMedCrossRefGoogle Scholar
  10. Archer, T, Fredriksson, A, Jonsson, G, Lewander, T, Mohammed, AK, Ross, SB, Soderberg, U 1986aCentral noradrenaline depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the ratPsychopharmacology88141146CrossRefGoogle Scholar
  11. Archer, T, Jonsson, G, Minor, BG, Post, C 1986bNoradrenergic-serotonergic interactions and nociception in the ratEur J Pharmacol120295307CrossRefGoogle Scholar
  12. Berlan, M, Rascol, O,  et al. 1989Alpha 2-adrenergic sensitivity in Parkinson’s diseaseClin Neuropharmacol12138144PubMedGoogle Scholar
  13. Berridge, CW, Dunn, AJ 1990DSP-4-induced depletion of brain norepinephrine produces opposite effects on exploratory behaviour 3 and 14 days after treatmentPsychopharmacology100504508PubMedCrossRefGoogle Scholar
  14. Dolphin, AC, Jenner, P, Marsden, CD 1976aThe relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or α-methyl-p-tyrosine pre-treated micePharmacol Biochem Behav4661670CrossRefGoogle Scholar
  15. Dolphin, AC, Jenner, P, Marsden, CD 1976bNoradrenaline synthesis from L-DOPA in rodents and its relationship to motor activityPharmacol Biochem Behav5431439CrossRefGoogle Scholar
  16. Dooley, DJ, Bittiger, H, Hauser, KL, Bischoff, SL, Waldmeier, PC 1983aAlteration of central alpha 2- and beta-adrenergic receptors in the rat after DSP4, a selective noradrenergic neurotoxinNeuroscience9889898CrossRefGoogle Scholar
  17. Dooley, DJ, Mogilnicka, E, Delini-Stula, A, Waechter, F, Truog, A, Wood, J 1983bFunctional supersensitivity to adrenergic agonists in the rat after DSP-4, a selective noradrenergic neurotoxinPsychopharmacology8115CrossRefGoogle Scholar
  18. Fornai, F, Bassi, L, Torracca, MT, Alessandri, MG, Scalori, V, Corsini, GU 1996Region- and neurotransmitter-dependent species and strain differences in DSP4-induced monoamine depletion in rodentsNeurodegeneration5241249PubMedCrossRefGoogle Scholar
  19. Fornai, F, Alessandri, MG, Torracca, MT, Bassi, L, Corsini, GU 1997Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletionsJ Pharmacol Exp Ther283100107PubMedGoogle Scholar
  20. Fredriksson, A, Archer, T 1994MPTP-induced behavioural and biochemical deficits: a parametric analysisJ Neural Transm (PD Sect)7123132CrossRefGoogle Scholar
  21. Fredriksson, A, Archer, T 2000Effects of clonidine and α-adrenoceptor antagonists on motor activity in DSP4-treated mice. II. Interactions with apomorphineNeurotox Res1249259PubMedGoogle Scholar
  22. Fredriksson, A, Archer, T 2003Effect of postnatal iron administration on MPTP-induced behavioural deficits and neurotoxicity: behavioural enhancement by L-Dopa-MK-801 co-administrationBehav Brain Res1393146PubMedCrossRefGoogle Scholar
  23. Fredriksson, A, Palomo, T, Chase, TN, Archer, T 1999aTolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonistsJ Neural Transm106283300CrossRefGoogle Scholar
  24. Fredriksson, A, Plaznik, A, Sundström, E, Jonsson, G, Archer, T 1990MPTP-induced hypoactivity in mice: reversal by L-DopaPharmacol Toxicol67295301PubMedCrossRefGoogle Scholar
  25. Fredriksson, A, Schroder, N, Eriksson, P, Izquierdo, I, Archer, T 2001Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficitsParkinsonism Rel Disord797105CrossRefGoogle Scholar
  26. Glowinski, J, Iversen, LL 1966Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brainJ Neurochem13655669PubMedGoogle Scholar
  27. Goldstein, M, Engel, J,  et al. 1983Therapeutic potentials of centrally acting dopamine and alpha 2-adrenoceptor agonistsJ Neural Transm18257263Google Scholar
  28. Heal, DJ, Butler, SA, Prow, MR, Buckett, WR 1993Quantification of alpha 2-adrenoceptors in rat brain after short-term DSP-4 lesioningEur J Pharmacol2493741PubMedCrossRefGoogle Scholar
  29. Heikkila, RE, Sieber, B-A, Manzino, L, Sonsalla, PK 1989Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouseMol Chem Neuropathol10171183PubMedCrossRefGoogle Scholar
  30. Henry, B, Crossman, AR,  et al. 1998Characterisation of enhanced behavioural responses to L-DOPA following repeated administration in the 6-hydroxydopamine model of Parkinson’s diseaseExp Neurol151334342PubMedCrossRefGoogle Scholar
  31. Jonsson, G, Hallman, H 1982Response of central monoamine neurons following an early neurotoxic lesionBibl Anat237692PubMedGoogle Scholar
  32. Jonsson, G, Hallman, H, Ponzio, F, Ross, SB 1981DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine) – a useful denervation tool for central and peripheral noradrenaline neuronsEur J Pharmacol72173188PubMedCrossRefGoogle Scholar
  33. Jonsson, G, Hallman, H, Sundström, E 1982Effects of the noradrenaline neurotoxin DSP4 on the postnatal development of central noradrenaline neurons in the ratNeuroscience728952907PubMedCrossRefGoogle Scholar
  34. Kirk, R 1995Experimental design: procedures for the behavioural sciencesBrooks/ColeBelmont, CAGoogle Scholar
  35. Langston, JW 1985MPTP neurotoxicity: an overview and characterization of phases of toxicityLife Sci36201206PubMedCrossRefGoogle Scholar
  36. Latigan, AJ, Marien, MR, Colpaert, FC 1992Suppression of nigrostriatal and mesolimbic dopamine release in vivo following noradrenaline depletion by DSP-4: a microdialysis studyLife Sci50995999CrossRefGoogle Scholar
  37. Marien, MR, Briley, M, Colpaert, FC 1993Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in miceEur J Pharmacol236487489PubMedCrossRefGoogle Scholar
  38. Marien, MR, Colpaert, FC, Rosenquist, AC 2004Noradrenergic mechanisms in neurodegenerative diseases: a theoryBrain Res Rev453878PubMedCrossRefGoogle Scholar
  39. Nishi, K, Kondo, T, Narabayashi, H 1991Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by L-dopaNeurosci Lett123244247PubMedCrossRefGoogle Scholar
  40. Persson, T, Waldeck, B 1970Further studies on the possible interaction between dopamine and noradrenaline containing neurons in the brainEur J Pharmacol11315320PubMedCrossRefGoogle Scholar
  41. Ponzio, F, Hallman, H, Jonsson, G 1981Noradrenaline and dopamine interaction in rat brain during developmentMed Biol59161169PubMedGoogle Scholar
  42. Post, C, Persson, ML, Archer, T, Minor, BG, Danysz, W, Sundström, E 1987Increased antinociception by alpha-adrenoceptor drugs after spinal cord noradrenaline depletionEur J Pharmacol137107116PubMedCrossRefGoogle Scholar
  43. Riekkinen, M, Kejonen, K,  et al. 1998Reduction of noradrenaline impairs attention and dopamine depletion slows response in Parkinson’s diseaseEur J Neurosci1014291435PubMedCrossRefGoogle Scholar
  44. Ross, SB 1976Long-term effects of N-2-chloroethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurons in the rat brain and heartBr J Pharmacol58521527PubMedGoogle Scholar
  45. Ross, SB, Renyi, L 1976On the long-lasting inhibitory effect of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) on the active uptake of noradrenalineJ Pharmacol Pharmac28458459Google Scholar
  46. Shoulson, Y, Chase, TN 1976Clonidine and the antiparkinsonian response to L-Dopa or piribedilNeuropharmacology152527PubMedCrossRefGoogle Scholar
  47. Sonsalla, PK, Heikkila, RE 1986The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in miceEur J Pharmacol129339345PubMedCrossRefGoogle Scholar
  48. Sundström, E, Fredriksson, A, Archer, T 1990Chronic neurochemical and behavioural changes in MPTP-lesioned C57 Bl/6 mice: a model for Parkinson’s diseaseBrain Res528181188PubMedCrossRefGoogle Scholar
  49. Tarsy, D, Parkes, JD,  et al. 1975Clonidine in Parkinson’s diseaseArch Neurol32134136PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • T. Archer
    • 1
    • 2
  • A. Fredriksson
    • 3
  1. 1.Department of PsychologyUniversity of GöteborgGöteborgSweden
  2. 2.Department of Health and Behavioural ScienceKalmar UniversityKalmarSweden
  3. 3.Department of NeurosciencePsychiatry Ulleråker, University of UppsalaUppsalaSweden

Personalised recommendations